Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Absci Corporation (ABSI : NSDQ)
 
 • Company Description   
Absci Corporation is a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design. Absci Corporation is based in NEW YORK.

Number of Employees: 157

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.77 Daily Weekly Monthly
20 Day Moving Average: 3,757,293 shares
Shares Outstanding: 127.56 (millions)
Market Capitalization: $353.34 (millions)
Beta: 2.01
52 Week High: $6.33
52 Week Low: $2.01
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -2.46% -7.75%
12 Week 12.83% -5.34%
Year To Date 5.73% -0.97%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
18105 SE MILL PLAIN BLVD
-
VANCOUVER,WA 98683
USA
ph: 360-949-1041
fax: -
investors@absci.com http://www.absci.com
 
 • General Corporate Information   
Officers
Sean McClain - Chief Executive Officer and Director
Zachariah Jonasson - Chief Financial Officer
Todd Bedrick - Chief Accounting Officer
Frans van Houten - Director
Karen McGinnis - Director

Peer Information
Absci Corporation (CORR.)
Absci Corporation (RSPI)
Absci Corporation (CGXP)
Absci Corporation (BGEN)
Absci Corporation (GTBP)
Absci Corporation (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00091E109
SIC: 8731
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/13/25
Share - Related Items
Shares Outstanding: 127.56
Most Recent Split Date: (:1)
Beta: 2.01
Market Capitalization: $353.34 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.13 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.68 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/13/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.78
Price/Cash Flow: -
Price / Sales: 73.38
EPS Growth
vs. Year Ago Period: 4.55%
vs. Previous Quarter: 16.00%
Sales Growth
vs. Year Ago Period: 31.29%
vs. Previous Quarter: 77.29%
ROE
06/30/25 - -
03/31/25 - -53.69
12/31/24 - -48.98
ROA
06/30/25 - -
03/31/25 - -45.89
12/31/24 - -42.12
Current Ratio
06/30/25 - -
03/31/25 - 5.72
12/31/24 - 4.67
Quick Ratio
06/30/25 - -
03/31/25 - 5.72
12/31/24 - 4.67
Operating Margin
06/30/25 - -
03/31/25 - -2,232.13
12/31/24 - -2,274.06
Net Margin
06/30/25 - -
03/31/25 - -2,232.13
12/31/24 - -2,274.06
Pre-Tax Margin
06/30/25 - -
03/31/25 - -2,231.01
12/31/24 - -2,272.52
Book Value
06/30/25 - -
03/31/25 - 1.56
12/31/24 - 1.56
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.01
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.34
12/31/24 - 0.70
 

Powered by Zacks Investment Research ©